Benlysta-120mg (Belimumab Vials) 120mg

Benlysta 120mg vials contain belimumab, a prescription biologic used to treat certain autoimmune conditions. This sterile injectable formulation is designed for healthcare professional administration. Store between 2-8°C to maintain potency. Always follow healthcare provider guidance when using.

Strength

120mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

GlaxoSmithKline UK Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Belimumab, the active ingredient in Benlysta 120mg vials, is commonly prescribed for autoimmune conditions like lupus (systemic lupus erythematosus) and other related disorders. It helps reduce abnormal immune system activity by targeting specific immune cells. Patients often ask, 'what is belimumab used for' when prescribed this medication. This treatment is typically recommended when other therapies have not been effective.

Side Effects

Belimumab works by modulating the immune system to decrease inflammation and immune response. Many patients notice gradual improvement in symptoms over time with consistent use. Some may experience mild injection-site reactions or flu-like symptoms initially. Effects vary by individual, and regular monitoring is recommended.

Precautions & Warnings

Benlysta 120mg vials should be handled and administered by trained healthcare professionals in a clinical setting. Patients with active infections or weakened immune systems should discuss risks with their doctor. Always inform your healthcare provider about current medications and medical history before starting treatment.

Avoid Interactions

Belimumab may interact with other immunosuppressants or biologics, potentially increasing infection risk. Live vaccines should be avoided during treatment due to reduced immune response. Alcohol and certain over-the-counter medications may also interact; consult your healthcare provider for personalized advice.

Frequently Asked Questions

Benlysta 120mg is administered as an intravenous infusion by a healthcare professional in a clinical setting.

Common effects may include nausea, diarrhea, fever, or reactions at the injection site.

Patients with active infections should consult their doctor before starting or continuing belimumab.

Pregnant or breastfeeding patients should discuss risks and benefits with their healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.